IMPROVING THE PRIORITIZATION PROCEDURE OF PATIENTS WITH COVID-19 IN HOSPITALS BASED ON DECISION-MAKING TECHNIQUES: A SYSTEMATIC REVIEW
Keywords:Convalescent-Plasma, COVID-19, MCDM, Telemedicine, Prioritization
Coronavirus-specific antibodies can be detected in the blood of people who have recently recovered from coronavirus disease-2019 (COVID-19). Convalescent-Plasma (CP) transfusion process proved that it's among the most efficient protocols, and it's used in hospitals to treat various infections and diseases. Several medical issues have been addressed due to the growing interest in creating Artificial Intelligence (AI) applications. However, considering the virus's enormous potential harm to global public health, such uses are insufficient. This proposed systematic review and meta-analysis aims to obtain an overview of COVID-19, highlight the limits of decision-making approaches, and give healthcare professionals information about the technique's advantages. Between 2016 and 2021, five databases, namely IEEE Xplore, Web of Science, PubMed, Science Direct, and Scopus, were utilized to run four sequences of search queries. As a result, 477 studies are found to be relevant. Only six studies were thoroughly examined and included in this review after screening articles and using proper inclusion criteria, highlighting the lack of research on this crucial topic. Studies' findings were reviewed to identify the gaps in all the evaluated papers. Motivations, problems, constraints, suggestions, and case examples were thoroughly examined. This study seeks to answer how we support the researchers with collected information for managing transfusion of the highest quality CP to the most critical COVID-19 patients across telemedicine hospitals.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
IJCI applies the Creative Commons Attribution (CC BY) license to articles. The author of the submitted paper for publication by IJCI has the CC BY license. Under this Open Access license, the author gives an agreement to any author to reuse the article in whole or part for any purpose, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and source are properly cited. This facility helps in re-use and ensures that journal content is available for the needs of research.
If the manuscript contains photos, images, figures, tables, audio files, videos, etc., that the author or the co-authors do not own, IJCI will require the author to provide the journal with proof that the owner of that content has given the author written permission to use it, and the owner has approved that the CC BY license being applied to content. IJCI provides a form that the author can use to ask for permission from the owner. If the author does not have owner permission, IJCI will ask the author to remove that content and/or replace it with other content that the author owns or has such permission to use.
Many authors assume that if they previously published a paper through another publisher, they have the right to reuse that content in their PLOS paper, but that is not necessarily the case – it depends on the license that covers the other paper. The author must ascertain the rights he/she has of a specific license (a license that enables the author to use the content). The author must obtain written permission from the publisher to use the content in the IJCI paper. The author should not include any content in her/his IJCI paper without having the right to use it, and always give proper attribution.
The accompanying submitted data should be stated with licensing policies, the policies should not be more restrictive than CC BY.
IJCI has the right to remove photos, captures, images, figures, tables, illustrations, audio, and video files, from a paper before or after publication, if these contents were included in the author's paper without permission from the owner of the content.